FYARRO
AADi Bioscience, Inc.
Trademark Registered: 2022-08-09
Trademark Application Details
STATEMENT OF USE - TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88984193 |
| Registration Number | 6815686 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Aaron D. Hendelman |
| Attorney Docket Number | 45455-TM1006 |
| Law Office Assigned | N30 |
| Employee Name | BLACK, MILDRED ELIZABE |
Timeline
| 2019-08-30 | Application Filed |
| 2020-07-28 | Published for Opposition |
| 2022-02-21 | Date of First Use |
| 2022-05-06 | Location: TMO LAW OFFICE 121 |
| 2022-05-06 | Status: Live/Pending |
| 2022-05-07 | Transaction Date |
| 2022-08-09 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  AADi Bioscience, Inc. |
| Address | 17383 Sunset Blvd., Suite A250 Pacific Palisades DE 90272 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in oncology; pharmaceutical preparations for the treatment of physiological diseases |
| GS0051 | Pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in oncology; pharmaceutical preparations for the treatment of physiological diseases |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2019-09-03 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-09-12 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2019-12-04 | 3 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2019-12-11 | 4 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2019-12-11 | 5 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-12-11 | 6 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2020-06-08 | 7 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2020-06-16 | 8 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-06-24 | 9 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-06-24 | 10 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2020-06-24 | 11 CNSA P: |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-07-08 | 12 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2020-07-28 | 13 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2020-07-28 | 14 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2020-09-22 | 15 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2021-02-23 | 16 EEXT I:Incoming Correspondence |
| SOU EXTENSION 1 FILED | 2021-02-23 | 17 EXT1 S: |
| SOU EXTENSION 1 GRANTED | 2021-02-23 | 18 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-02-25 | 19 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2021-09-20 | 20 EEXT I:Incoming Correspondence |
| SOU EXTENSION 2 FILED | 2021-09-20 | 21 EXT2 S: |
| SOU EXTENSION 2 GRANTED | 2021-09-20 | 22 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-09-22 | 23 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2022-03-21 | 24 EISU I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2022-03-21 | 25 EEXT I:Incoming Correspondence |
| TEAS REQUEST TO DIVIDE RECEIVED | 2022-03-21 | 26 ERTD I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2022-04-01 | 27 AITU A:Allowance for Publication |
| ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST | 2022-04-05 | 28 INCD O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2022-04-11 | 29 TROA I:Incoming Correspondence |
| DIVISIONAL REQUEST RECEIVED | 2022-03-21 | 30 DRRR I:Incoming Correspondence |
| DIVISIONAL PROCESSING COMPLETE | 2022-05-06 | 31 DPCC D:Assigned to Examiner |
| USE AMENDMENT FILED | 2022-03-22 | 32 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2022-05-06 | 33 SUPC I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2022-06-01 | 34 DOCK D:Assigned to Examiner |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2022-07-05 | 35 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2022-07-06 | 36 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2022-08-09 | 37 R.PR A:Allowance for Publication |
| NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2022-08-09 | 38 NRCC E:E-Mail |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 FYARRO 98195404 not registered Live/Pending |
AADi Bioscience, Inc. 2023-09-25 |
 FYARRO 88984193 not registered Live/Pending |
AADi Bioscience, Inc. 2019-08-30 |
 FYARRO 88599810 not registered Live/Pending |
AADi Bioscience, Inc. 2019-08-30 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 